Ozempic, Mounjaro and hair loss: how long should you wait before a hair transplant?

Key findings

• 40% higher risk of non-scarring hair loss with GLP-1 drugs (pooled OR 1.40, 95% CI 1.33–1.48) — Viquez Burboa et al., Skin Appendage Disorders 2026
• Telogen effluvium is the main type (adjusted OR 1.76); the authors link it mainly to nutrient shortfalls during weight loss — same study
• 6.91 vs 5.04 cases per 1,000 person-years in adults with type 2 diabetes on GLP-1 drugs vs SGLT-2 inhibitors — BMJ 2026
• Shedding starts 2–3 months after a trigger and resolves within 3–6 months, with full recovery of density in acute cases — Liyanage & Sinclair, Cosmetics 2016
• Most people can keep taking their GLP-1 before elective surgery, but should not be operated on during dose escalation — multi-society guidance, 2024

What the studies show

Two large 2026 analyses agree: people on GLP-1 drugs lose hair more often than comparable people who are not. The extra risk is real but moderate — most users do not lose noticeable hair.

In drug-safety report databases, semaglutide and tirzepatide carried the strongest hair-loss signal of the GLP-1 drugs (reporting odds ratios 2.46 and 1.73), according to the same meta-analysis. These databases show which side effects get reported, not how often they happen, so they cannot say which drug is safer for your hair.

One limit to keep in mind: the BMJ study only included adults with type 2 diabetes, so its numbers may not match people who take these drugs for weight loss alone.

Why GLP-1 drugs make hair shed

The drug itself is probably not the main cause; fast weight loss is. The 2026 meta-analysis concludes that the extra hair loss is "primarily mediated by weight loss-induced micronutrient deficiency." Three things point the same way:

• Big, fast weight loss. In the STEP 1 trial, people on semaglutide 2.4 mg lost 14.9% of their body weight over 68 weeks, against 2.4% on placebo (Wilding et al., NEJM 2021). Hair follicles react to that kind of change the way they react to other body stress.
• Eating much less. "Crash dieting with severe protein-calorie malnutrition can precipitate hair loss," notes a dermatology review (Liyanage & Sinclair, 2016). GLP-1 drugs cut appetite sharply, so protein intake can drop without people noticing.
• Low nutrient levels. After weight-loss surgery — the closest well-studied comparison — 57% of patients had hair loss, and it was linked to low ferritin, zinc and folic acid (Zhang et al., Obesity Surgery 2021; 18 studies, 2,538 patients).

This shedding is called telogen effluvium. A shock to the body pushes many growing hairs into their resting phase at once, and those hairs fall out together a few months later. The follicles are not destroyed, which is why the hair usually comes back.

Will the hair grow back?

Usually, yes. "In acute TE, the shedding resolves within 3–6 months and the hair density recovers completely" (Liyanage & Sinclair, 2016). Another review reports remission in about 95% of acute cases (Asghar et al., Cureus 2020).

After weight-loss surgery, the pattern looks similar: hair loss started on average 3.4 months after the operation and stopped at about 9 months, and in that study new hair grew back in all patients within 15 months of follow-up (Guo et al., cited in Zhang et al., 2021).

Two exceptions are worth knowing:

• Shedding that lasts more than 6 months is called chronic telogen effluvium. It can carry on for years and is worth a dermatologist visit.
• Pattern hair loss can surface at the same time. The 2026 meta-analysis also found more androgenetic alopecia in GLP-1 users (aOR 1.64). That kind of loss does not grow back on its own, and it is the kind a hair transplant can treat. Why the two are linked is not yet clear.

How long to wait before a hair transplant

Wait until the shedding has fully stopped and your weight has been stable for a while. No study has yet tested a specific waiting time for GLP-1 users, so the rule below is Foxpare's reading of the evidence on telogen effluvium — not a trial result. Ask your surgeon to confirm it for your case.

The typical sequence:

1. Dose increase — first 4–8 weeks; no elective surgery
2. Shedding starts — 2–3 months after the trigger
3. Shedding settles — usually within 3–6 months
4. Ready to plan — shedding stopped, weight stable, 6+ months since onset

The dose-increase window comes from the 2024 surgical guidance; the shedding timings come from dermatology reviews of telogen effluvium.

Why transplanting during active shedding is a mistake

1. You cannot see your real pattern yet. Hair that is only resting looks like hair that is gone. A plan made during shedding can over-estimate the area to fill and use more donor grafts than you need — and donor hair does not grow back.
2. Surgery is itself a shedding trigger. Dermatology reviews list "surgical trauma" among the classic triggers of telogen effluvium (Liyanage & Sinclair, 2016). Operating in the middle of one episode stacks a second stress on top.
3. Much of the hair may come back by itself. In acute cases density recovers completely, which can change how many grafts you need, or whether you need surgery at all.

Before you book

• Shedding has stopped (hair in the shower and on the pillow back to your normal)
• Your weight has been stable, and you are past the dose-increase phase of your GLP-1
• Blood tests checked with your doctor: ferritin, zinc and folic acid were the markers linked to hair loss after weight-loss surgery
• Ideally, 6 months or more since the shedding began, so that any chronic telogen effluvium has had time to show
• Your surgeon knows you take a GLP-1, which dose, and since when

When you are ready, our clinic finder shows Ministry-registered providers in Turkey that match your budget and city.

If you are still on a GLP-1 on surgery day

You usually do not need to stop it, but you should not have surgery while you are still increasing the dose. GLP-1 drugs slow stomach emptying, and food left in the stomach raises the risk of aspiration "during general anesthesia and deep sedation," according to 2024 guidance from five societies, including the American Society of Anesthesiologists (ASA, October 2024).

What the guidance says:

• Most patients should keep taking their GLP-1 before elective surgery.
• Avoid the dose-escalation phase, which "typically lasts four to eight weeks"; elective surgery should wait until it has passed and stomach side effects have settled.
• Wait if you have nausea, vomiting, abdominal pain or constipation until they go away.
• Higher-risk patients, such as those on higher doses with more stomach side effects, should follow a liquid-only diet for 24 hours before the procedure.

Most hair transplants are done under local anaesthesia, but many clinics also offer sedation. If yours does, tell the clinic in advance that you take a GLP-1 so the anaesthetist can plan for it. If you are travelling for surgery, keep in mind that nausea on a flight day and a liquid diet the day before can be harder to manage abroad.

References

1. Viquez Burboa GU, Flores Guillén MAR, Duardo González VS. GLP-1 receptor agonists and alopecia: a systematic review and meta-analysis of incidence, risk, subtypes, and mechanisms. Skin Appendage Disorders. 2026. doi:10.1159/000553070. PMID 42621629
2. Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation. BMJ. 2026. doi:10.1136/bmj-2026-100077
3. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021. doi:10.1056/NEJMoa2032183
4. Liyanage D, Sinclair R. Telogen effluvium. Cosmetics. 2016;3(2):13. doi:10.3390/cosmetics3020013
5. Asghar F, Shamim N, Farooque U, Sheikh H, Aqeel R. Telogen effluvium: a review of the literature. Cureus. 2020;12(5):e8320. doi:10.7759/cureus.8320
6. Zhang W, Fan M, Wang C, et al. Hair loss after metabolic and bariatric surgery: a systematic review and meta-analysis. Obesity Surgery. 2021;31:2649–2659. PMID 33675022
7. American Society of Anesthesiologists and four partner societies. Multi-society clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative period. October 2024. ASA news release

Information only — not medical advice. Talk to your prescriber and your surgeon about your own situation.